

AdvaMed

Advanced Medical Technology Association

UDI Challenge for Non-Sterile Implantable Devices

- Mary Gray, RAC
 Project Manager Regulatory Affairs | DePuy Synthes Spine
- Amy Delk
 Director, Regulatory Affairs | Stryker Corporation
- Mike Donoghue
 Vice President Trauma Fixation Strategic Business Unit/Advanced Surgical Devices | Smith & Nephew
- Jackie Rae Elkin
 Global Process Owner Standard Product Identification | Medtronic, Inc.

Overview



- UDI implementation challenges that manufacturers of non-sterile spine, trauma, craniomaxillofacial, and extremities sets face
- Description of 4 compliance strategies companies may use to meet UDI requirement to adequately identify devices through distribution and use
- Recommendation for additional time for UDI implementation for products related to these orthopedic sets

Objectives



Review the four UDI alternative solutions

- Allow direct marking regulations (21 CFR 801.45) for non-sterile implants
- Provide adequate time to implement alternative solutions

Impact to Public Health



- It is estimated that sets are used annually in:
 - 464,000 thoracolumbar procedures
 - 291,000 cervical procedures
 - 1,750,000 trauma procedures
 - 214,000 craniomaxillofacial procedures
 - 19,000 small joint (fingers, wrists, ankles) procedures
 - 2,738,000 total procedures
- Based on our data we estimate there are 221,130 sets currently in distribution

Why are Implants Organized in Non-sterile Sets?



- Procedures require a large number of implant options available to provide patients with customized solutions
 - Multiple sizes, lengths, and diameters needed due to anatomic variability
 - Pre-contoured implant choices to optimize outcomes
 - Many types of implant options may be used in a given procedure
- Sets are configured in an organized fashion so that OR personnel can correctly, quickly and efficiently identify the necessary implants and instruments
 - Ensures the correct choice of implant
 - Quick access to implant options minimizes OR time thus reducing anesthesia time, blood loss, and infection risk
- Sets are designed to be efficiently reprocessed and replenished for subsequent use
 - Improves surgical turnover time
 - Minimizes hospital need for storage space

Challenges



- 1. UDI-labeled packaging is removed prior to implants being placed in sets
- 2. Sets are assembled to meet specific orders
 - Hospitals, specific patients or surgeon preferences
 - This results in hundreds of potential configurations for one set
- 3. Sets are designed to be:
 - Sterilized prior to each use,
 - Typically consist of up to hundreds of implants, and
 - Are configured for easy identification and selection by surgeon/OR staff

Challenges



- Implants not used in surgical procedure remain in set and are reprocessed for subsequent use
- 5. Following cleaning and decontamination, but prior to subsequent use, set is replenished to ensure all necessary implants are available for next surgical procedure
- 6. Sets may be hospital owned (equity) or manufacturer owned (consignment/loaner)
 - Each set may contain 1000 implants
 - Surgeons typically use 3 to 15 sets per procedure
 - Surgeon may only use a few implants from each set
 - Hospital bills for each implant as it is used
 - Hospitals prefer consignment/loaner due to significant cost of sets

Clinical Group Perspective



- Met with AAOS, AANS, NASS, OTA and AORN via Web Conference on June 9
- We understand they have communicated directly with FDA
- Overarching concern expressed by clinicians: Do not lengthen surgical time and continue rapid access to implantable devices

UDI Solution Challenges



- UDI method should be informative, easy to use and minimize disruption in surgery flow and not increase OR time
- Sets should arrive and flow through hospital system (central sterile processing, set build, etc.) and to OR with UDI solution in place
- After surgery, unused contents should continue to be identified by a UDI
- Items within set can cycle through distribution chain repeatedly
- UDI solution should be usable when no manufacturer representative is in OR
- UDI solution should allow for data capture when item is implanted
- The solution may take a combination of several methods: DPM (with exemptions where necessary due to space or other considerations), sterile packaging, and data carrier tags or strips
- In order to meet patient needs, sets need to be rapidly replenished between procedures



Questions and Answers

Four Compliance Strategies




Companies will need the flexibility to pursue one or more strategies simultaneously or separately:

- 1. Data Carrier Tags product remains UDI-tagged until use
- Data Carrier Strips product group remains UDI-tagged until use
- Sterilization of Implants product individually packaged and marked with UDI
- 4. Direct Part Mark product surface bears the UDI
 - With exemption from PI marking for medium size implants and PI and DI marking for small implants
 - Accompanied by implant mapping and recording process
 - DI on caddy and inventory control sheet

Data Carrier Tags



- Tag is affixed to product by manufacturer and bears UDI information in human readable and/or AIDC technology
- OR staff removes tag and captures UDI information manually or via scanner
- Scanned information can be electronically captured and downloaded into EHR system
- Product is intended to remain tagged until point of use;
 once removed it cannot typically be re-attached



Data Carrier Strips



- Implants from the same LOT are attached to plastic strip where each implant has its own compartment
- Individual compartments can be snapped off strip as needed
- The plasticized paper UDI label remains with each implant on strip until point of use
- Plastic strips are loaded into trays
- OR staff break off and remove needed number of implants from plastic strip and retrieve UDI information



Individual Sterile Package



- Sterile supplied devices is common practice for a majority of implantable medical devices, including some spine and trauma sets
- It is not common practice for large set configurations due to:
 - increased packaging waste
 - limited space in O.R.
 - increased O.R. time due to removing packaging for each implant





Application of 21CFR 801.45 Direct Marking



- Implants are etched with a human readable and/or AIDC readable UDI
- Larger implants that have sufficient space for the UDI in human readable format will have the device identifier (DI) and production identifier (PI) marked
- Medium implants may have sufficient space for only the device identifier to be marked and will require an exemption from PI marking*
- Small implants will not have sufficient space for any human readable text and will require an exemption from PI and DI*marking







Figure B: Medium Implant with only DI

*The device identifier for small and medium implants can be documented in medical record using an inventory mapping and recording process – see next slides


Implant Mapping and Recording process



PERI-LOC* Small Fragment Screw Caddy

2.7	mm L	ocking	Screws	2.7	mm N	ion-loci	king Screws	3.5	mm L	ocking	Screws
738	32-23)	ox -		738	32-30)			738	7382-50XX		
L	QTY	BC	GTIN	L	QTY	BC	GTIN	L	QTY	BC	GTIN
10			12345678912345	10		8	26584562241165	10			68654645564060
12		8	45698745301248	12		Si.	32165041654654	12		Si.	49946846510615
14		8	18952401435687	14		S.	44585460146541	14		8	98791465106548
16		8	35982406580014	15		S.	65464561452021	16		8	56874892465464
18		8	92014568446852	18		8	54680498406224	18		8	87987489489498
20		3	22547789632155	20		3	58478974031215	20		3	21549794126655
22		8	99568744123651	22		S.	54878960315341	22		8	89789809419541
24		8	32459986521474	24		S.	89401604894103	24		8	54654650549616
26		8	35871699582245	26			34867406131065	26		8	34874848948848
28			16891335846085	28		8	15849804851584	28		8	98798744165416
30		M	95886854225847	30			48060644654655	30		8	77489109889048
32		8	32589655412588	32		8	49654654046548	32		8	18499846545646
34		8	15986544856325	34		3	24894054164804	34		8	21654654165146
35		8	75698852100365	36		8	87414089401605	36			22415458558444
38		8	93256678745214	38		3	76540541061216	38		3	87984564564655
40			88622215885477	40			65105410651561	40			33154151313000

- 1. Surgeon calls for the desired implant which is retrieved by the scrub tech
- Circulating nurse will document the type and quantity of each implant used on the inventory control sheet.
- 3. As a secondary check, the circulating nurse can compare the implant tray map (located on back of inventory sheet) to the actual implant tray to validate the implants used.
- 4. Circulating nurse documents the information from the inventory sheet into the EHR.



Implant Mapping and **Recording process**



	3.5mm Locking Reconstruction Plates 7182-26XX							
н	QTY	BC	GTINDI	GTN/H				
12		逐	1246878912945					
10		遻	45898745301248					
8		经	35940406580014					
8		逐	92014568446852					
4		Sec.	92014568446852					

	Smm Compression Plates, Non-locking						
	2-94X GTY	DC .	G-TIN	GTINA			
)		屡	26584582241165				
		Ø.	32165041654654				
		屡	65464561452021				
		變	54880488408224				
		屡	54880488408224				
		屡	65464561462021				
		蒙	54680498406224				
0		Ø.	54880488408224				

	3.5mm Compression Plates, Locking 7182-97XX							
	QTY		G-TN	GTIN/N				
3		逐	26584562241165					
4		篴	32165041654654					
5		鬉	65464661452021					
6		经	54680498406224					
7		經	54680496406224					
8		旞	65464561452021					
9		旞	54680486406224					
10		經	54600466406704					

nm Proximal Humerus Locking Plates 2-94XX					3.5mm Locking One-third Tubular Plates 7182-90XX						
QTY	0C	G-TIN	GTINPI	н	qty	80	G-TIN	GTINHI			
	8	26584562241165		4		1	26584562241165				
	嫪	32165041654654		6		嫪	32165041654654				
	嫪	65464561452021		7		经	65464561452021				
	變	5480490408224		8		经	54680408408224				
				10		经	5480408408224				

OC 3.5mm Lateral Proximal Tibia Plate Se

718	1 Plate 80-04)				718	MC P
H	QfY	BC	GTINOI	GTNH1	н	qt
13			12346878912346		4	
10		2	45898745301248		8	Г
8		Ø.	35960406580014		10	
4		2	92014568446852		13	
DE	RIJ (V+ 6	mell Executed	Olete Ceddy		

	3			100	nt Pla	es		
ИΧ	X			718	90 - 05X	X		
Y	BC	GTINDI	GTN-PI	н	QTY	00	G-TIN	GTINAN
	2	12346878912346		4			26584562241165	
_	925				-	1925		
	200	45696745301248		8			32165041654654	
	38 E				-	1000		
	200	35900405580014		10			65464561452021	
	(82%)				-	1025		
	2.5	92014568449852		13		100	5480488408224	
10	C*S	mall Fragment	Plate Caddy					

☆smith&nephew

- Inventory control sheets contain the item number, bar code, and the GTIN device identifier
- Where possible, the 'production identifier' will be directly marked in human readable text on the implant
- The PI can be recorded or photographed at time of usage to capture the information
- The production identifier can be recorded in the inventory control sheet and transferred to electronic medical record



Questions and Answers




- Strategies to achieve UDI compliance for non-sterile implants stored in trays will be extremely complex, costly and will require substantial time to implement
- Compliance strategies will also require significant changes in way hospitals/ OR staff currently manage orthopedic surgeries



The product development lifecycles are greatly impacted by the Design Controls necessary under the Quality System Regulation and are driving the need for additional time for implementation

Application of Design Control to Design Process



Ref: FDA Design Control Guidance March 11, 1997



Other considerations driving the necessity of an extension or exception to comply with the UDI Rule:

- Operational impacts
 - Purchasing controls for new technologies and equipment
 - Supplier capacity
 - Production and process change controls
 - Validation (IQ, OQ, PQ) and verification
 - Manufacturing Transfer
- Regulatory review and market authorization
- Training of manufacturer representatives and healthcare professionals



- Regardless of solution chosen, compliance strategies will be a dynamic shift in the way companies produce, distribute and track product
- These enormous changes, coupled with the volume of Implants, Class II, and Class III medical devices that must be compliant, makes any solution a multi-year endeavor
- Without additional time for UDI implementation orthopedic sets will be unable to be shipped preventing patient access to these products thus impacting the public health



- For these reasons, on behalf of its affected members, AdvaMed recommends two additional years to implement the proposed Orthopedic Set solutions for non-sterile implants
- Individual companies will submit exception and alternative placement requests as needed



Final Rule Compliance Timelines							
Final Rule Requirement	Label & Date Format Compliance Date	Direct Marking Compliance Date	Unpackaged, Non-sterile Orthopedic Set Proposed Compliance Date				
Class III Devices	September 24, 2014	September 24, 2016	September 24, 2016				
Implants, Life Supporting, Life Sustaining Devices	September 24, 2015	September 24, 2015	September 24, 2017				
Class II Devices (not included above)	September 24, 2016	September 24, 2018	September 24, 2018				
Class I Devices, Exempt, Not classified	September 24, 2018	September 24, 2020	N/A				
Date Format for Devices Not Subject UDI	September 24, 2018	N/A	N/A				

Impact to Public Health



- It is estimated that sets are used annually in:
 - 464,000 thoracolumbar procedures
 - 291,000 cervical procedures
 - 1,750,000 trauma procedures
 - 214,000 craniomaxillofacial procedures
 - 19,000 small joint (fingers, wrists, ankles) procedures
 - 2,738,000 total procedures
- Based on our data we estimate there are 221,130 sets currently in distribution

Questions For FDA



- With compliance deadlines rapidly approaching, companies need to know:
 - Will FDA allow direct marking regulations (21 CFR 801.45) for non-sterile implants?
 - Will FDA grant, for non-sterile product in orthopedic sets:
 - Two year compliance extension, or
 - Time limited exception, or
 - Enforcement discretion

